Traumatic brain injury in elderly population: A global systematic review and meta-analysis of in-hospital mortality and risk factors among 2.22 million individuals

IF 12.5 1区 医学 Q1 CELL BIOLOGY
Zixuan Ma , Zhenghui He , Zhifan Li , Ru Gong , Jiyuan Hui , Weiji Weng , Xiang Wu , Chun Yang , Jiyao Jiang , Li Xie , Junfeng Feng
{"title":"Traumatic brain injury in elderly population: A global systematic review and meta-analysis of in-hospital mortality and risk factors among 2.22 million individuals","authors":"Zixuan Ma ,&nbsp;Zhenghui He ,&nbsp;Zhifan Li ,&nbsp;Ru Gong ,&nbsp;Jiyuan Hui ,&nbsp;Weiji Weng ,&nbsp;Xiang Wu ,&nbsp;Chun Yang ,&nbsp;Jiyao Jiang ,&nbsp;Li Xie ,&nbsp;Junfeng Feng","doi":"10.1016/j.arr.2024.102376","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Traumatic brain injury (TBI) among elderly individuals poses a significant global health concern due to the increasing ageing population.</p></div><div><h3>Methods</h3><p>We searched PubMed, Cochrane Library, and Embase from database inception to Feb 1, 2024. Studies performed in inpatient settings reporting in-hospital mortality of elderly people (≥60 years) with TBI and/or identifying risk factors predictive of such outcomes, were included. Data were extracted from published reports, in-hospital mortality as our main outcome was synthesized in the form of rates, and risk factors predicting in-hospital mortality was synthesized in the form of odds ratios. Subgroup analyses, meta-regression and dose-response meta-analysis were used in our analyses.</p></div><div><h3>Findings</h3><p>We included 105 studies covering 2217,964 patients from 30 countries/regions. The overall in-hospital mortality of elderly patients with TBI was 16 % (95 % CI 15 %-17 %) from 70 studies. In-hospital mortality was 5 % (95 % CI, 3 %-7 %), 18 % (95 % CI, 12 %-24 %), 65 % (95 % CI, 59 %-70 %) for mild, moderate and severe subgroups from 10, 7, and 23 studies, respectively. A decrease in in-hospital mortality over years was observed in overall (1981–2022) and in severe (1986–2022) elderly patients with TBI. Older age 1.69 (95 % CI, 1.58–1.82, <em>P</em> &lt; 0.001), male gender 1.34 (95 % CI, 1.25–1.42, <em>P</em> &lt; 0.001), clinical conditions including traffic-related cause of injury 1.22 (95 % CI, 1.02–1.45, <em>P</em> = 0.029), GCS moderate (GCS 9–12 compared to GCS 13–15) 4.33 (95 % CI, 3.13–5.99, <em>P</em> &lt; 0.001), GCS severe (GCS 3–8 compared to GCS 13–15) 23.09 (95 % CI, 13.80–38.63, <em>P</em> &lt; 0.001), abnormal pupillary light reflex 3.22 (95 % CI, 2.09–4.96, <em>P</em> &lt; 0.001), hypotension after injury 2.88 (95 % CI, 1.06–7.81, <em>P</em> = 0.038), polytrauma 2.31 (95 % CI, 2.03–2.62, <em>P</em> &lt; 0.001), surgical intervention 2.21 (95 % CI, 1.22–4.01, P = 0.009), pre-injury health conditions including pre-injury comorbidity 1.52 (95 % CI, 1.24–1.86, <em>P</em> = 0.0020), and pre-injury anti-thrombotic therapy 1.51 (95 % CI, 1.23–1.84, <em>P</em> &lt; 0.001) were related to higher in-hospital mortality in elderly patients with TBI. Subgroup analyses according to multiple types of anti-thrombotic drugs with at least two included studies showed that anticoagulant therapy 1.70 (95 % CI, 1.04–2.76, <em>P</em> = 0.032), Warfarin 2.26 (95 % CI, 2.05–2.51, <em>P</em> &lt; 0.001), DOACs 1.99 (95 % CI, 1.43–2.76, <em>P</em> &lt; 0.001) were related to elevated mortality. Dose-response meta-analysis of age found an odds ratio of 1.029 (95 % CI, 1.024–1.034, <em>P</em> &lt; 0.001) for every 1-year increase in age on in-hospital mortality.</p></div><div><h3>Conclusions</h3><p>In the field of elderly patients with TBI, the overall in-hospital mortality and its temporal-spatial feature, the subgroup in-hospital mortalities according to injury severity, and dose-response meta-analysis of age were firstly comprehensively summarized. Substantial key risk factors, including the ones previously not elucidated, were identified. Our study is thus of help in underlining the importance of treating elderly TBI, providing useful information for healthcare providers, and initiating future management guidelines. This work underscores the necessity of integrating elderly TBI treatment and management into broader health strategies to address the challenges posed by the aging global population.</p></div><div><h3>Review registration</h3><p>PROSPERO CRD42022323231</p></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":null,"pages":null},"PeriodicalIF":12.5000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568163724001946","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Traumatic brain injury (TBI) among elderly individuals poses a significant global health concern due to the increasing ageing population.

Methods

We searched PubMed, Cochrane Library, and Embase from database inception to Feb 1, 2024. Studies performed in inpatient settings reporting in-hospital mortality of elderly people (≥60 years) with TBI and/or identifying risk factors predictive of such outcomes, were included. Data were extracted from published reports, in-hospital mortality as our main outcome was synthesized in the form of rates, and risk factors predicting in-hospital mortality was synthesized in the form of odds ratios. Subgroup analyses, meta-regression and dose-response meta-analysis were used in our analyses.

Findings

We included 105 studies covering 2217,964 patients from 30 countries/regions. The overall in-hospital mortality of elderly patients with TBI was 16 % (95 % CI 15 %-17 %) from 70 studies. In-hospital mortality was 5 % (95 % CI, 3 %-7 %), 18 % (95 % CI, 12 %-24 %), 65 % (95 % CI, 59 %-70 %) for mild, moderate and severe subgroups from 10, 7, and 23 studies, respectively. A decrease in in-hospital mortality over years was observed in overall (1981–2022) and in severe (1986–2022) elderly patients with TBI. Older age 1.69 (95 % CI, 1.58–1.82, P < 0.001), male gender 1.34 (95 % CI, 1.25–1.42, P < 0.001), clinical conditions including traffic-related cause of injury 1.22 (95 % CI, 1.02–1.45, P = 0.029), GCS moderate (GCS 9–12 compared to GCS 13–15) 4.33 (95 % CI, 3.13–5.99, P < 0.001), GCS severe (GCS 3–8 compared to GCS 13–15) 23.09 (95 % CI, 13.80–38.63, P < 0.001), abnormal pupillary light reflex 3.22 (95 % CI, 2.09–4.96, P < 0.001), hypotension after injury 2.88 (95 % CI, 1.06–7.81, P = 0.038), polytrauma 2.31 (95 % CI, 2.03–2.62, P < 0.001), surgical intervention 2.21 (95 % CI, 1.22–4.01, P = 0.009), pre-injury health conditions including pre-injury comorbidity 1.52 (95 % CI, 1.24–1.86, P = 0.0020), and pre-injury anti-thrombotic therapy 1.51 (95 % CI, 1.23–1.84, P < 0.001) were related to higher in-hospital mortality in elderly patients with TBI. Subgroup analyses according to multiple types of anti-thrombotic drugs with at least two included studies showed that anticoagulant therapy 1.70 (95 % CI, 1.04–2.76, P = 0.032), Warfarin 2.26 (95 % CI, 2.05–2.51, P < 0.001), DOACs 1.99 (95 % CI, 1.43–2.76, P < 0.001) were related to elevated mortality. Dose-response meta-analysis of age found an odds ratio of 1.029 (95 % CI, 1.024–1.034, P < 0.001) for every 1-year increase in age on in-hospital mortality.

Conclusions

In the field of elderly patients with TBI, the overall in-hospital mortality and its temporal-spatial feature, the subgroup in-hospital mortalities according to injury severity, and dose-response meta-analysis of age were firstly comprehensively summarized. Substantial key risk factors, including the ones previously not elucidated, were identified. Our study is thus of help in underlining the importance of treating elderly TBI, providing useful information for healthcare providers, and initiating future management guidelines. This work underscores the necessity of integrating elderly TBI treatment and management into broader health strategies to address the challenges posed by the aging global population.

Review registration

PROSPERO CRD42022323231

老年人群中的创伤性脑损伤:对 222 万人的院内死亡率和风险因素的全球系统回顾和荟萃分析。
背景:随着人口老龄化的加剧,老年人的创伤性脑损伤(TBI)已成为全球关注的重大健康问题:方法:我们检索了 PubMed、Cochrane Library 和 Embase 数据库中从数据库开始到 2024 年 2 月 1 日的内容。纳入了在住院环境中进行的研究,这些研究报告了患有创伤性脑损伤的老年人(≥60 岁)的院内死亡率和/或确定了预测此类结果的风险因素。从已发表的报告中提取数据,将院内死亡率作为主要结果,以比率的形式进行综合分析,并将预测院内死亡率的风险因素以几率比的形式进行综合分析。我们在分析中使用了亚组分析、元回归和剂量反应元分析:我们纳入了 105 项研究,涵盖 30 个国家/地区的 2,217,964 名患者。在70项研究中,老年创伤性脑损伤患者的总体院内死亡率为16%(95% CI为15%-17%)。轻度、中度和重度亚组的院内死亡率分别为 5%(95% CI,3%-7%)、18%(95% CI,12%-24%)和 65%(95% CI,59%-70%),分别来自 10、7 和 23 项研究。在总体(1981-2022 年)和重度(1986-2022 年)老年创伤性脑损伤患者中,院内死亡率逐年下降。年龄较大 1.69 (95% CI, 1.58 to 1.82, P < 0.001),性别为男性 1.34 (95% CI, 1.25 to 1.42, P < 0.001),临床症状包括交通相关的受伤原因 1.22 (95% CI, 1.02 to 1.45, P = 0. 029),GCS 中度(1981-2022 年)和重度(1986-2022 年)。029)、GCS 中度(GCS 9-12 与 GCS 13-15 相比)4.33(95% CI,3.13 至 5.99,P<0.001)、GCS 重度(GCS 3-8 与 GCS 13-15 相比)23.09(95% CI,13.80 至 38.63,P<0.001)、瞳孔光反射异常 3.22(95% CI,2.09 至 4.96,P<0.001)、伤后低血压 2.88(95% CI,1.06 至 7.81,P = 0.038)、多发性创伤 2.31(95% CI,2.03 至 2.62,P <0.001)、手术干预 2.21(95% CI,1.22 至 4.01,P = 0.009)、伤前健康状况(包括伤前合并症) 1.52 (95% CI, 1.24 to 1.86, P = 0.0020)、受伤前抗血栓治疗 1.51 (95% CI, 1.23 to 1.84, P < 0.001)与老年创伤性脑损伤患者较高的院内死亡率有关。根据至少纳入两项研究的多种抗血栓药物类型进行的亚组分析表明,抗凝疗法 1.70(95% CI,1.04 至 2.76,P = 0.032)、华法林 2.26(95% CI,2.05 至 2.51,P < 0.001)、DOACs 1.99(95% CI,1.43 至 2.76,P < 0.001)与死亡率升高有关。年龄的剂量-反应荟萃分析发现,年龄每增加1岁,院内死亡率的几率比为1.029(95% CI,1.024至1.034,P<0.001):首次全面总结了老年创伤性脑损伤患者的总体院内死亡率及其时空特征、根据损伤严重程度划分的亚组院内死亡率以及年龄的剂量反应荟萃分析。研究发现了大量关键风险因素,包括以前未阐明的因素。因此,我们的研究有助于强调治疗老年创伤性脑损伤的重要性,为医护人员提供有用的信息,并启动未来的管理指南。这项工作强调了将老年创伤性脑损伤治疗和管理纳入更广泛的健康战略的必要性,以应对全球人口老龄化带来的挑战:PROCROPERO:CRD42022323231。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ageing Research Reviews
Ageing Research Reviews 医学-老年医学
CiteScore
19.80
自引率
2.30%
发文量
216
审稿时长
55 days
期刊介绍: With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends. ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research. The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信